Skip to main navigation
Orchestra BioMed logo

Close

Investor Relations
  • Who We Are
    • Our Approach
    • Our People
    • Careers
  • Our Innovations
    • Pipeline
    • Therapeutic Areas
    • Virtue® SAB
    • BackBeat CNT™
    • FreeHold Retractors
  • Investor Relations
  • News & Events
    • News Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Corporate Governance
    • Documents & Charters
    • Leadership Team
    • Board of Directors
    • Committee Composition
  • Financial & Filings
    • SEC Filings
    • Annual Reports and Proxy Satements
  • IR Resources
    • Email Alerts
    • Contact IR
  • Contact Us
Menu - sns
Twitter Linkedin

Investor Relations

News Releases

Orchestra BioMed™ Completes $34 Million Financing to Accelerate Product Pipeline Development and Advance Partnerships
July 10, 2019
Series B-1 Round Led by Perceptive, RTW and Soleus Capital with Strategic Participation from Terumo Corporation Secures $64 Million in 2019 Capital Inflows, Including $30 Million Upfront Payment from Terumo Partnership Financing Structure Provides Up to an Additional $57 Million in Follow-On
Orchestra BioMed™ Announces Global Strategic Partnership with Terumo Corporation for Development and Commercialization of Virtue® Sirolimus-Eluting Balloon
June 13, 2019
Virtue ®  SEB is expected to become a flagship therapeutic product for Terumo and will strengthen its broad US and global portfolio of interventional solutions Terms of the partnership include substantial up-front and milestone payments, equity investment, a strong commitment to global clinical
Orchestra BioMed™ Presents Clinical Data at EuroPCR 2019 Demonstrating Safety and Efficacy of BackBeat Cardiac Neuromodulation Therapy (CNT)
May 23, 2019
Novel implantable bioelectronic treatment delivers immediate, substantial, and sustained reduction in blood pressure Data showed 14.2 mmHg reduction in 24-hour ambulatory systolic blood pressure at three months and 23.4 mmHg reduction in office cuff systolic blood pressure out to two years Therapy
Orchestra BioMed™ Receives FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon (SEB)
April 24, 2019
First and only non-coated sirolimus-eluting angioplasty balloon system to show promising clinical results Potential to offer significant advantages for treatment of coronary in-stent restenosis (ISR), a condition that represents over 10% of total interventional procedures New Hope, PA – Orchestra
Orchestra BioMed™ to Present at the 2019 Bioelectronic Medicine Forum
April 2, 2019
Panel presentation will provide an overview and outlook on BackBeat Cardiac Neuromodulation Therapy, a potent, novel bioelectronic treatment for hypertension Hypertension, considered the #1 contributing risk factor for death by WHO, is a global epidemic that affects over 100 million Americans and
Orchestra BioMed™ to Present at Oppenheimer 29th Annual Healthcare Conference
March 13, 2019
- Presentation with live audio webcast on Tuesday, March 19, 2019 at 3:20 p.m. ET - Webcast Link:  https://www.veracast.com/webcasts/opco/healthcare2019/82115698694.cfm New Hope, PA – Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing advanced
Orchestra BioMed™ to Present at the Piper Jaffray Healthcare Conference
November 20, 2018
New Hope, PA – Orchestra BioMed, Inc., (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing advanced therapeutic solutions to address major unmet medical needs, today announced that David Hochman, Chairman and Chief Executive Officer, will present a corporate overview
David Hochman, Chairman and Chief Executive Officer, will present a corporate overview at the Piper Jaffray Healthcare Conference on Thursday, November 29, 2018 at 9:30 a.m. EST in New York, NY
November 20, 2018
Event:  Piper Jaffray Healthcare Conference Date:  Thursday, November 29, 2018 at 9:30 a.m. EST Webcast Link:   https://event.webcasts.com/starthere.jsp?ei=1222275&tp_key=5bdf221dd0
Orchestra BioMed™ Announces Completion of $41 Million Financing
November 15, 2018
Capital proceeds to support late-stage clinical development of lead cardiovascular product candidates for artery disease and hypertension Financing structure provides for up to an additional $23 million in follow-on financing from existing investors New Hope, PA – Orchestra BioMed, Inc.,
Orchestra BioMed™ Announces AHA 2018 Presentation on BackBeat® Cardiac Neuromodulation Therapy (CNT)
November 8, 2018
Novel Treatment Delivers Immediate, Substantial, and Sustained Reduction in Blood Pressure Potential to Become a Broadly Applicable Therapy for Device-Based Hypertension Management New Hope, PA – Orchestra BioMed, Inc., (“Orchestra BioMed” or the “Company”), a biomedical innovation company

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Page 2
  • Current page 3
  • Page 4
  • Next page next ›
  • Last page last »
Displaying 21 - 30 of 40
Orchestra BioMed logo
  • Footerlink - who we are

    Who We Are Our Approach Our People Careers
  • Footerlink - our innovations

    Our Innovations Pipeline Therapeutic Areas Virtue® SAB BackBeat CNT™ FreeHold Retractors
  • Footerlink - news & events

    Investor Relations Overview News & Events Stock Information Corporate Governance Financial & Filings IR Resources
  • Footerlink - contact us

    Contact Us
Menu - sns
Twitter Linkedin

© 2023 Orchestra BioMed Inc. Virtue®, BackBeat CNT™ FreeHold Duo®, FreeHold Trio® and Orchestra BioMed™ are trademarks of Orchestra BioMed.
All other trademarks are trademarks of their respective owners.
SM-0020 Rev 01

Btn - disclaimer

Disclaimer